Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
ALX Oncology Inc.
Pfizer
Pfizer
Aurigene Discovery Technologies Limited
Aurigene Discovery Technologies Limited
Pheon Therapeutics
M.D. Anderson Cancer Center
Kestrel Therapeutics, Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of California, Irvine
Revolution Medicines, Inc.
Seagen Inc.
Alterome Therapeutics, Inc.
Orano Med LLC
RasCal Therapeutics, Inc.
Pfizer
Xencor, Inc.
M.D. Anderson Cancer Center
Cartography Biosciences
Accent Therapeutics
Mirati Therapeutics Inc.
National Institutes of Health Clinical Center (CC)
H. Lee Moffitt Cancer Center and Research Institute
Pheon Therapeutics
City of Hope Medical Center
City of Hope Medical Center
M.D. Anderson Cancer Center
Northwell Health
Novartis
Novartis
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
AstraZeneca
Chongqing Precision Biotech Co., Ltd
HUYABIO International, LLC.
HUYABIO International, LLC.
Medigen Biotechnology Corporation
Elicio Therapeutics
Revolution Medicines, Inc.
Eli Lilly and Company
GONGCHU Biotechnology Co., Ltd
Novita Pharmaceuticals, Inc.
City of Hope Medical Center
Compugen Ltd
Columbia University
Sapience Therapeutics
Thomas Jefferson University